By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In response, Novo is reorganizing its leadership team following the surprise ouster of Chief Executive Lars Fruergaard ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Employers are grappling with the ripple effect of an increasingly popular weight loss treatment. Pharmacy benefit leaders at ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...